脑膜瘤VEGFR-2表达水平与疾病复发及预后的关系-东南大学学报医学版

脑膜瘤VEGFR-2表达水平与疾病复发及预后的关系

单位：琼海市人民医院神经外科, 海南琼海 571400

分类号：R739.45

出版年·卷·期（页码）：2022·41·第三期（339-344）

摘要：

目的：探讨脑膜瘤血管内皮细胞生长因子受体-2（VEGFR-2）表达水平与疾病复发和预后的关系。方法：选取本院2016年8月至2018年8月收治的143例脑膜瘤患者为脑膜瘤组，另取同期收治的因脑外伤切除脑组织的69例患者为对照组。比较两组组织VEGFR-2表达情况。随访3年，根据预后将脑膜瘤患者分成预后良好组、预后不良组，利用多元Cox回归分析脑膜瘤预后的危险因素。通过Kaplan-Meier生存曲线与Log-rank χ²检验分析VEGFR-2表达与患者复发率、累积生存率的关系。结果：脑膜瘤组VEGFR-2阳性率为78.32%，高于对照组的14.49%（P<0.05）。预后不良组年龄≥50岁、肿瘤最大径≥5 cm、包绕血管神经、海绵窦受累、视神经管受累、VEGFR-2阳性、WHO Ⅲ级占比高于预后良好组，手术全切、术后辅助治疗占比低于预后良好组（P<0.05）。多因素Cox回归分析提示，肿瘤最大径≥5 cm、包绕血管神经、海绵窦受累、VEGFR-2阳性、WHO Ⅲ级是脑膜瘤预后不良危险因素，手术全切、术后辅助治疗是预后保护因素（P<0.05）。VEGFR-2阳性组复发率高于VEGFR-2阴性组（P<0.05）。结论：脑膜瘤VEGFR-2表达增高，且阳性表达者3年疾病复发率更高，但对累积生存率未见明显影响。

Objective: To investigate the relationship between the expression of vascular endothelial growth factor receptor-2(VEGFR-2) and disease recurrence and prognosis in meningiomas. Methods: 143 patients with meningioma treated in our hospital from August 2016 to August 2018 were selected as meningioma group, and 69 patients with brain tissue removed due to brain trauma in the same period were selected as control group. The expression of VEGFR-2 in the two groups was compared and followed up for 3 years. According to the prognosis, they were divided into good prognosis group and poor prognosis group, multivariate Cox regression model was used to analyze the prognostic risk factors of meningiomas. Kaplan-Meier survival curve and Log-rank χ² test were used to analyze the relationship between VEGFR-2 expression and recurrence rate, and cumulative survival rate was analyzed. Results: The positive rate of VEGFR-2 in the meningioma group was 78.32%, which was higher than 14.49% in the control group(P<0.05). The poor prognosis group had more cases with age ≥ 50 years old, the maximum tumor diameter ≥ 5 cm, vascular nerve, cavernous sinus involvement, optic canal involvement, VEGFR-2 positive and WHO grade Ⅲ than those in the good prognosis group, and had lower proportions of total resection and postoperative adjuvant therapy than those in the good prognosis group(P<0.05). Multiple Cox regression model analysis showed that the maximum tumor diameter ≥ 5 cm, surrounding blood vessels and nerves, involvement of cavernous sinus, positive VEGFR-2 and WHO grade Ⅲ were the risk factors for poor prognosis of meningiomas, and total resection and postoperative adjuvant treatment were the protective factors for prognosis(P<0.05). The recurrence rate of VEGFR-2 positive group was higher than that of VEGFR-2 negative group(P<0.05). Conclusion: The positive expression of VEGFR-2 is increased in meningiomas, and the 3-year disease recurrence rate was higher in those with positive expression, however, it has no significant effect on the cumulative survival rate.

参考文献：

[1] ALGHAMDI M,LI H,OLIVOTTO I,et al.Atypical meningioma:referral patterns,treatment and adherence to guidelines[J].Can J Neurol Sci,2017,44(3):283-287.
[2] NOWOSIELSKI M,GALLDIKS N,IGLSEDER S,et al.Diagnostic challenges in meningioma[J].Neuro Oncology,2017,19(12):1588-1598.
[3] 陈东,冯林森,王羽丰.VEGF/VEGFR2信号通路调控机制的研究进展[J].癌症进展,2019,17(7):748-751.
[4] 马从乾,王雅,王娜,等.LINC00152通过调节VEGFR2的表达对血管瘤内皮细胞生长、增殖、迁移和侵袭的影响[J].癌症进展,2019,17(3):284-290.
[5] 徐鹏霄,郑淑芳.免疫组化与分子病理学[M].北京:人民军医出版社,2011:64.
[6] 戴大鹏,孙晓阳.脑膜瘤术后复发的相关因素研究进展[J].现代医学,2013,41(7):517-520.
[7] 王冠一,贺晓生.第四脑室脑膜瘤的诊断与治疗研究进展[J].中华神经医学杂志,2020,19(4):413-416.
[8] 刘朝辉,高晓虹.血管内皮生长因子及其受体的研究进展[J].中国药物与临床,2017,14(8):63-65.
[9] 刘厚杰,万经海.脑膜瘤恶性进展的分子机制[J].国际肿瘤学杂志,2018,45(8):494-498.
[10] LI F,JIE H,JI D.Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer[J].Oncol Lett,2017,14(1):89-96.
[11] SEOK J,YOON S,LEE S,et al.The oncometabolite d-2-hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway[J].Int J Oncol,2019,54(2):753-763.
[12] 范广明,张文.非典型脑膜瘤的临床特征及术后复发影响因素分析[J].解放军预防医学杂志,2017,35(2):134-136.
[13] 曹明,朱勋,朱晓明,等.非典型脑膜瘤患者无进展生存期影响因素的Meta分析[J].中华神经外科杂志,2020,36(6):628-635.
[14] 孙菲,汪建林,于静萍.靶向调控HIF-1α-VEGF-VEGFR-2通路治疗恶性肿瘤的新进展[J].国际肿瘤学杂志,2017,44(6):456-459.
[15] WANG M,JIANG X.Sumoylation of vascular endothelial growth factor receptor 2 inhibits the proliferation,migration,and angiogenesis signaling pathway in non-small cell lung cancer[J].Anti-Cancer Drug,2020,31(5):492-499.
[16] DRONOVA T A,BABYSHKINA N N,ZAVYALOVA M V,et al.Vascular endothelial growth factor receptor 2(VEGFR2) contributes to tamoxifen resistance in estrogen-positive breast cancer patients[J].Mol Biol,2021,55(1):102-108.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录